News

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.

Galderma showcased relabotulinumtoxinA and abobotulinumtoxinA at TOXINS 2026, highlighting innovative injectables with sustained results and high patient satisfaction.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

The survey revealed significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Tina Alster, MD; Daniel Schlessinger, MD; and Mary Lupo, MD, shared their insights on upcoming aesthetic innovations at the American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Explore the latest advancements in dermatology for 2026, focusing on clinical innovation, emerging research, and practical insights for improved patient care.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of January.

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe atopic dermatitis (AD).

Atopia Therapeutics advances ATP-R13 as a promising oral therapy for atopic dermatitis (AD), showing significant efficacy and enhanced patent protection.

The 2025 Inflammatory Skin Disease Summit (ISDS) unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.

James Del Rosso, DO, discusses innovative topical therapies for dermatologic conditions.

New research uncovers significant knowledge gaps among Chinese patients with acne regarding oral medications, highlighting the need for improved education strategies.

DELTA CARE 1 is the first phase 3 investigation of a pan–Janus kinase inhibitor specifically for lichen sclerosus.

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.

Obagi Medical's ALOHA Program launches Obagi saypha MagIQ, pioneering real-world evaluation of a new hyaluronic acid filler.

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.

This review of the latest dermatologic studies includes insights on a novel ultrasound technique for midface rejuvenation, sirolimus for reducing cSCC risk, dermatologists' role in social media dysmorphia, and more.

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.

Michael O'Donoghue, MD, discusses tailoring PDT for AK, emphasizing patient preferences and flexible treatment strategies.

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

BOTOX Cosmetic's FDA approval for platysma bands revolutionizes non-surgical neck rejuvenation, offering dermatologists a new tool for effective patient care.